The Analyst Landscape: 6 Takes On Silence Therapeutics
Analysts’ ratings for Silence Therapeutics (NASDAQ:SLN) over the last quarter vary from bullish to bearish, as provided by…
What 7 Analyst Ratings Have To Say About Silence Therapeutics
Silence Therapeutics (NASDAQ:SLN) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from…
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a…
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Shattuck Labs (NASDAQ:STTK) stock moved upwards by 93.8% to $4.09 during Wednesday’s regular session. The company’s market…
Is This A Miracle Drug For ‘Sticky Cholesterol’? Analysts Applaud Safety, Efficacy Of Silence Therapeutics’ Heart Disease Candidate
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a) (Lp(a), levels at or over 150 nmol/L and stable atherosclerotic
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Cellectis (NASDAQ:CLLS) shares moved upwards by 188.6% to $2.8 during Wednesday’s regular session. Trading volume for this…
Where Silence Therapeutics Stands With Analysts
Silence Therapeutics (NASDAQ:SLN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell
• IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.